Sarepta Elevidys Shipment Controversy

News

Sarepta Will Resume Gene Therapy Shipments

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular disorder who can walk, after the FDA recommended the removal of a voluntary hold that was placed on the therapy.

Fierce Pharma · 7d

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

Managed Healthcare Executive · 6d

Sarepta to Pause Shipments of the Gene Therapy Elevidys

Sarepta Therapeutics stock sinks further Tuesday after halting shipment of bestselling drug Elevidys

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

7don MSN

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta Therapeutics' (SRPT) stock continued to sink Monday, down about 5% in early trade, following a rough end to last week ...

3don MSN

Sarepta falls as FDA plans to investigate death of child who received Elevidys

The U.S. Food and Drug Administration said on Friday that it is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta Therapeutics ( NASDAQ: SRPT) gene therapy for Duchenne ...

FiercePharma1mon

FDA investigates patient deaths after treatment with Sarepta's Duchenne ...

FDA investigates patient deaths after treatment with Sarepta's Duchenne gene therapy Elevidys By Angus Liu Jun 25, 2025 10:26am Sarepta Therapeutics gene therapy U.S. FDA FDA investigation ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results